2024-07-25 08:40:31 ET
Summary
- Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs.
- Approval of tirzepatide for weight management in China and the EU opens up new markets for the company.
- Despite strong growth potential, Eli Lilly's stock remains pricey, with upcoming earnings report potentially changing the investment outlook.
One of the most amazing growth stories, especially if you ignore the semiconductor space, over the past couple of years, has been pharmaceutical giant Eli Lilly and Company ( LLY ). In just the past year, shares of the stock are up 88.5%. This comes on the back of tremendous growth driven by its weight loss drugs. As I detailed in a prior article , this has the potential to generate tremendous value for the company and its investors. But up until recently, the conversation has really only been focused on the US market....
Read the full article on Seeking Alpha
For further details see:
Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China